MICHAEL JOHNS



VP OF COMMUNICATIONS



GENTIVA HEALTH SERVICES



It is almost impossible to think about Thalidomide without associating

it with the tragic birth defects of the late 1950s and early 1960s. But

that tragedy is now very dated and unlikely to recur as long as

Thalidomide's distribution remains controlled and secure, as it is

currently through the so-called STEPS program. The greater challenge is

the fact that, while the FDA approved Thalidomide initially for the

treatment of leprosy skin sores, a number of clinical studies suggest

that it is a ...